Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa

NCT07174726 is registered in ClinicalTrials.gov with Beacon Therapeutics as lead sponsor.

NCT NCT07174726
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07174726 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa
Lead sponsor
Beacon Therapeutics
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 10, 2025
Completion date
December 30, 2030
Enrollment
10 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

x-linked retinitis pigmentosa (xlrp)